Babesia divergens–like Infection, Washington State by Herwaldt, Barbara L. et al.
Most reported U.S. zoonotic cases of babesiosis have
occurred in the Northeast and been caused by Babesia
microti. In Washington State, three cases of babesiosis
have been reported previously, which were caused by WA1
(for “Washington 1”)-type parasites. We investigated a case
of babesiosis in Washington in an 82-year-old man whose
spleen had been removed and whose parasitemia level
was 41.4%. The complete 18S ribosomal RNA gene of the
parasite was amplified from specimens of his whole blood
by polymerase chain reaction. Phylogenetic analysis
showed the parasite is most closely related, but not identi-
cal, to B. divergens (similarity score, 99.5%), a bovine par-
asite in Europe. By indirect fluorescent-antibody testing, his
serum reacted to B. divergens but not to B. microti or WA1
antigens. This case demonstrates that babesiosis can be
caused by novel parasites detectable by manual examina-
tion of blood smears but not by serologic or molecular test-
ing for B. microti or WA1-type parasites. 
H
undreds of zoonotic cases of babesiosis have been
reported in the United States, approximately 30 in
Europe, and a few elsewhere (1–14). Most of the reported
U.S. cases have been caused by Babesia microti, a parasite
of small mammals transmitted by Ixodes scapularis ticks,
and have occurred in the Northeast or, less commonly, the
upper Midwest (4). 
Few zoonotic cases of babesiosis have been reported in
the western United States (7–11). Specifically, in
Washington State, only three cases, two presumably tick-
borne and one associated with blood transfusion, have
been reported previously (7,8,10). The index tick-borne
case occurred in 1991 in Klickitat County, in south-central
Washington (7,8). The other two cases occurred in 1994:
one in a person transfused with infected erythrocytes and
the other in the implicated blood donor, who lived in King
County, in the western foothills of the Cascade Mountains
(10). All three of these cases were caused by WA1 (for
“Washington 1”)-type parasites (1,2,7–10,14) (Figure 1).
However, the etiologic agent of the case of babesiosis in
Washington in 2002 that we describe here is most closely
related, by molecular criteria, to B. divergens, a bovine
parasite in Europe (5,6).
Methods 
Serologic Testing
Serum specimens were tested at the Centers for
Disease Control and Prevention (CDC), in serial fourfold
dilutions, by indirect fluorescent-antibody (IFA) testing,
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Figure 1. Unrooted phylogenetic tree for the complete 18S rRNA
gene of selected Babesia spp. The tree was computed by using
the quartet puzzling maximum likelihood method of the TREE-
PUZZLE program. The scale bar indicates an evolutionary dis-
tance of 0.01 nucleotide substitutions per position in the sequence.
The GenBank accession numbers for the sequences used in the
analysis are as follows: B. divergens (6), AY046576; B. odocoilei,
AY046577; Babesia sp. EU1 (6), AY046575; the Babesia sp. from
the patient in Washington State, AY274114 (see arrow); B. microti,
U09833; WA1, from the index case of infection with WA1-type par-
asites (7,8), AF158700; and Theileria annulata, M64243. for reactivity to B. microti (15), WA1 (7), and B. divergens
antigens (6). The antigen sources were human isolates of
B. microti and WA1 and a bovine isolate of B. divergens
(Purnell strain [16]), which had been passaged in gerbils
(Mongolian jirds; Meriones unguiculatus) and adapted to
culture in bovine erythrocytes (17).
Animal Inoculation
To attempt to obtain an isolate of the parasite that
infected the patient (hereafter referred to as the patient’s
parasite), whole blood specimens, collected from him in
tubes containing the anticoagulant disodium EDTA, were
injected into hamsters (Mesocricetus auratus) and jirds.
Animal experimentation guidelines were followed. Both
hamsters and jirds are competent hosts for B. microti and
WA1-type parasites, and jirds are competent hosts for B.
divergens (18). No pretreatment specimens were available.
Refrigerated specimens collected on July 31, 2002 (the
date antibabesial therapy was begun [Table 1]), and August
1 were each injected intraperitoneally into two hamsters
(0.25 mL and 0.5 mL/animal, respectively) on August 2. A
specimen obtained on September 10 (15 days after therapy
was discontinued) was injected intraperitoneally into two
jirds (1 mL/animal) the next day. The animals were
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Table 1. Clinical data on selected dates for a patient in Washington State infected with a Babesia divergens-like parasite, 2002
a 
Date 
Temperature 
(°C) 
Hematocrit 
(%)
b 
Leukocyte 
count 
(10
9/L) 
Platelet 
count 
(10
9/L) 
Parasitemia 
level (%)
c 
Creatinine 
level 
(mg/dL)
d 
Total/direct 
bilirubin 
levels (mg/dL) 
Lactate 
dehydrogenase 
level (U/L)  Comments 
July 30   38.5  43  19.6  34  25.5
 c  8.5  10.2  4,283  Admitted to a 
community 
hospital 
July 31
e    40  21.2
f  21  41.4
 c  10.3  8.2/2.9    Babesiosis 
diagnosed; 
antibabesial 
therapy started 
(see text)
g 
July 31
h   39.9  36  18.5  25  28.2  11.1
i  9.9/3.1  6,674  6 U platelets 
transfused 
August 1  37.7  27  21.6  57  24.7  6.4  6.7/2.3  2,898  Began 
hemodialysis; 2 U 
packed 
erythrocytes 
transfused 
August 2  36.9  32  22.1  67  17.9  4.2  3.3/2.1  5,802   
August 3  37.5  29  17.2  96  13.6  7.3    2,423   
August 4  36.9  27  10.4  110    6.4  1.3/0.7     
August 5  37.6  26  9.9  135  11.9  9.0       
August 6  37.5  24  9.5  149  13.2  11.0      2 U packed 
erythrocytes 
transfused 
August 7  37.5  30  9.9  149    8.8       
August 8  37.9  30  9.2  204  7.7  11.2       
August 9  36.7  28  9.2  161
j    8.2      Discharged home 
                   
September 13    28  7.3  179    2.8       
November 1    39  6.0      1.7       
aNormal ranges for laboratory values at community hospital (July 30–31): creatinine, 0.7–1.5 mg/dL; total bilirubin, 0.1–1.0 mg/dL; lactate dehydrogenase, 100–200 
U/L. Normal ranges at University of Washington Medical Center (July 31–Aug. 9): creatinine, 0.3–1.2 mg/dL; total bilirubin, 0.1–1.0 mg/dL; direct bilirubin, 0.0–0.3 
mg/dL; lactate dehydrogenase, 0–190 U/L.  
bHematocrit normalized to values of 42% (Feb. 3, 2003) and 45% (June 27, 2003).  
cAll parasitemia levels were determined by the same person at the Centers for Disease Control and Prevention. Level for July 30 was determined from a peripheral smear 
made the next day (i.e., blood not fresh). The other pretreatment parasitemia level (i.e., from July 31 at community hospital) was determined from a smear made from 
fresh blood. 
dBaseline and posthospitalization creatinine values include: 1.6 mg/dL (Sept. 2001), 1.7 mg/dL (Feb. 3, 2003), and 1.6 mg/dL (June 27, 2003).  
eData obtained at community hospital.  
fLeukocyte differential: 74% segmented neutrophils, 9% lymphocytes, 8% atypical lymphocytes (including immunoblasts and plasmacytoid forms), 7% monocytes, 1% 
eosinophils, and 1% metamyelocytes. 
gOn Aug. 1, dosage regimen changed from clindamycin (1.2 g twice daily, by IV infusion) and quinine sulfate (650 mg thrice daily, by mouth), to clindamycin (600 mg 
four times daily, by IV infusion) and quinine (650 mg daily, by mouth). After patient was discharged from hospital on Aug. 9, therapy continued through Aug. 26; 
regimen: clindamycin (600 mg four times daily, by mouth) and quinine (650 mg daily, by mouth). Patient also treated with erythropoietin until Nov. 2002. 
 
hData obtained at University of Washington Medical Center.  
iDipstick analysis of urine specimen showed 3+ protein, 3+ blood, 3+ bilirubin, and 1+ ketones; and was positive for nitrites and leukocyte esterase. Microscopic 
examination showed granular casts and 1+ leukocytes. Culture demonstrated >10
5 colonies of Escherichia coli per milliliter of urine. The urinary tract infection was 
treated with ceftriaxone. 
jValue could be inaccurate; platelets clumped on blood smear. monitored for parasitemia, weekly for 8 weeks, by
examination of Giemsa-stained smears of blood obtained
by tail snip (hamsters) or toenail clip (jirds). Blood
obtained from the animals after the 8-week monitoring
period was examined by polymerase chain reaction (PCR;
see next section). 
DNA Extraction, Amplification, and Sequencing
DNA was extracted at CDC from whole blood speci-
mens collected from the patient in EDTA tubes, by using
the QIAamp DNA Blood Mini Kit (Qiagen Inc., Valencia,
CA); the DNA was stored at 4°C. The complete 18S ribo-
somal RNA (18S rRNA) gene from the patient’s parasite
was amplified by PCR, with a pair of apicomplexan 18S
rRNA-specific primers: CRYPTOF (5′-AACCTG-
GTTGATCCTGCCAGT-3′) and CRYPTOR (5′-
GCTTGATCCTTCTGCAGGTTCACCTAC-3′). PCR was
conducted with AmpliTaq Gold DNAPolymerase (Applied
Biosystems, Foster City, CA). The conditions for PCR
included 95ºC for 15 min, followed by 45 cycles of denat-
uration at 94°C for 30 s, annealing at 65°C for 30 s, and
extension at 72°C for 1.5 min. Final extension was done at
72°C for 9 min, followed by a hold step at 4°C. The ampli-
fication product was purified by using the StrataPrep DNA
Purification Kit (Stratagene, La Jolla, CA).
Both strands of the PCR product were sequenced by
using a set of internal primers. Sequencing reactions were
performed with the ABI PRISM BigDye Terminator Cycle
Sequencing Kit (Applied Biosystems), and reactions were
analyzed on the ABI 3100 automatic DNA sequencer
(Applied Biosystems). The resulting sequences were
assembled by using the program SeqMan II (DNASTAR,
Inc., Madison, WI). The GenBank accession number for
the sequence obtained by these methods for the patient’s
parasite is AY274114. 
Phylogenetic Analysis
The complete sequences of the 18S rRNA genes for B.
divergens;  B.  odocoilei, a parasite of white-tailed deer
(Odocoileus virginianus) (17,19); Babesia sp. EU1 (for
“European Union 1”) (6); B. microti; the WA1 parasite
from the index case of such infection (7,8); and Theileria
annulata were retrieved from the GenBank database
(Figure 1). The sequences were aligned with the sequence
for the patient’s parasite by using the program Clustal W,
version 1.83 (20). Phylogenetic analysis was performed
with the following programs: the PHYLIP package, which
includes versions 3.573c of CONSENSE, DNADIST,
DNAML, NEIGHBOR, and SEQBOOT (21); and version
5.1 of TREE-PUZZLE (22). The phylogenetic trees
inferred by these programs were drawn with the program
TreeView, version 1.6.6 (23).
Case Report
On July 30, 2002, an 82-year-old man in Kitsap
County (a peninsula of estuarine lowlands in Puget
Sound, in western Washington), was admitted to a com-
munity hospital. During the previous 4 days, he had noted
the gradual onset of chills (without fever), weakness,
malaise, anorexia, dysphagia, marked thirst, and urinary
dribbling. Until April or May 2002, he had been an avid
jogger. Although he had not had the energy to jog there-
after, he had continued to walk his dog daily; they walked
on a road around a lake that abutted his backyard, which
he kept “natural,” and on a neighbor’s wooded property.
He had an outdoor cat; had occasionally noted deer and
(in previous years) voles or shrews in his yard; did not live
near cattle; and had not traveled outside of Kitsap County
or Mason County, the adjacent southern county, in the pre-
vious couple of years. He had not noted ticks on his body
or received blood transfusions. His medical history
included longstanding hypertension; secondary renal
insufficiency; and incidental splenectomy in approximate-
ly 1990, when his distal pancreas, which had a benign
mass, was removed. 
When he was hospitalized on July 30, his temperature
was 38.5°C; pulse, 76 beats/min; blood pressure, 168/94
mm Hg; and respiratory rate, 18 breaths/min. He had scle-
ral icterus and dry mucous membranes from severe dehy-
dration. The salient laboratory data and information about
his clinical course are provided in Table l. Initial laborato-
ry testing showed many abnormalities, including marked
thrombocytopenia and elevated values of creatinine, biliru-
bin, and lactate dehydrogenase.
Babesiosis was diagnosed, when a peripheral smear
made on July 31 from blood collected on July 30 was
noted to have intraerythrocytic, ring-like trophozoites; the
level of parasitemia on a smear of fresh blood from July 31
was 41.4% (Table 1; Figure 2). On July 31, antibabesial
therapy was begun at the community hospital; he received
one dose of clindamycin (1,200 mg, by intravenous infu-
sion) and one dose of quinine sulfate (975 mg, by mouth;
the intended—i.e., ordered—dose was 650 mg). 
Later on July 31, he was transferred to the University
of Washington Medical Center. He continued therapy with
clindamycin and quinine, with periodic adjustments of the
dosage regimen (Table 1 footnote). In addition, he was
transfused with 6 U of platelets and 4 U of packed
erythrocytes. His acute renal failure (Table 1) was treated
with hemodialysis; it was attributed to acute tubular
necrosis from dehydration and intravascular hemolysis,
superimposed on chronic renal insufficiency from hyper-
tensive nephrosclerosis. His hospital course was also
notable for laboratory evidence, on August 1, of asympto-
matic, subendocardial ischemia and for pulmonary
edema. 
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he continued antibabesial therapy through August 26
(Table 1) and hemodialysis through early September. He
resumed jogging and walking in early October 2002 and
had remained well as of July 2003.
Results
Serologic Testing and Animal Inoculation
The patient’s serum did not react to B. microti or WA1
antigens but showed marked IFA reactivity to B. divergens
antigens, which slowly decreased during the 9-month mon-
itoring period (Table 2). Attempts to obtain an isolate of the
patient’s parasite, by injecting specimens of his blood into
hamsters and jirds, were unsuccessful (Table 2 footnote).
PCR analysis of blood from the inoculated animals, after
they had been monitored for 8 weeks, was negative. 
Molecular Findings
Amplification of the complete 18S rRNA gene of the
patient’s parasite yielded a specific product of approxi-
mately 1,700 bp. Sequence analysis showed that the gene
was 1,728 bases long. The sequences of the PCR products
from three blood specimens from the patient (Table 2),
each processed separately, were identical. The DNA
sequence also was verified by staff in an independent lab-
oratory, who had never worked with B. divergens or DNA
extracted from it. 
BLAST search confirmed that the sequence for the
patient’s parasite was not identical to any complete 18S
rRNA sequence in GenBank. The highest similarity score
(99.5%) was with B. divergens (GenBank no. AY046576);
the sequences for B. divergens and the patient’s parasite
differ by eight bases. 
In phylogenetic analysis (Figure 1), the patient’s para-
site clusters together with B. divergens. This group forms
a sister group to a cluster that includes B. odocoilei and
Babesia sp. EU1 (6). The clustering of the organisms was
the same, regardless of the taxonomic method used. The
alignment of the sequences used to construct the phyloge-
netic tree (Figure 1), after columns with gaps and unre-
solved characters were removed, had 1,651 columns; the
bases in 255 columns differed among the Babesia spp.
included in the analysis. The alignment may be requested
from the authors. Serial PCR and IFA data (Table 2)
showed that the patient had subpatent parasitemia and a
persistently high IFA titer (1:1,024) for at least 2 months
after his antibabesial therapy was stopped.
Discussion
This case of babesiosis had several unusual features.
First, it occurred in Washington State, rather than in the
Northeast, where most of the reported U.S. cases of
zoonotic babesiosis have occurred. Our case raises the
count for reported cases of babesiosis in Washington from
three to four (one bloodborne and three presumably tick-
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Figure 2. Panel of Babesia-infected erythrocytes photographed from pretreatment, Wright’s-Giemsa–stained smears of fresh blood
obtained from the patient on July 31, 2002. The mean corpuscular volume of the erythrocytes was 103 (normal range 80–100 µm3). Note
the multiply infected erythrocytes; the pleomorphism of the parasite; and the obtuse (divergent) angle formed by some of the paired struc-
tures, which, like the form in (F), is characteristic of B. divergens and related parasites isolated from various wild ruminants. The forms
of the parasite shown in the panel include: (A) ring-like trophozoite; (B) paired merozoites; (C) maltese-cross (tetrad); (D) various divid-
ing forms; (E) multiple merozoites; (F) appliqué (accolé) form on right border of the erythrocyte; (G) and (H) degenerate (crisis) forms. A
glass slide of a peripheral blood smear from July 31 has been deposited in the U.S. National Parasite Collection, Beltsville, Maryland;
the accession number (USNPC #) for the slide is 093041.00. borne cases). Second, the case was caused by a parasite
most closely related, by molecular criteria, to B.
divergens, a European bovine parasite (24), rather than to
WA1-type parasites, which caused the three previously
reported cases of babesiosis in the state. Third, the patient
whose case we describe survived, despite having multiple
risk factors for severe babesiosis and death: he was
elderly (82 years old), was asplenic, had a high level of
parasitemia (41.4%), and had multiorgan dysfunction that
included renal failure. 
Few cases of babesiosis in the western United States
have been reported previously; all occurred in Washington
or California. They include two tick-borne cases in
California in 1966 (25) and 1979 (26), as well as seven
tick-borne and two blood-transfusion–associated cases in
California and Washington from 1991 to 2000 (7–11).
Whereas the etiologic agents of the cases in 1966 and 1979
were not determined, the last nine cases were caused by
the CA1- and WA1-types of Babesia- (or Babesia-like)
piroplasms, which are distinct from each other but in the
same phylogenetic group. Although the appropriate
position for this clade in phylogenetic analyses of the
piroplasms remains unclear (14), the position is remote
from B. microti and B. divergens (11,14) (Figure 1).
The molecular characterization of our patient’s parasite
(Washington, 2002) showed that the sequence for the com-
plete 18S rRNAgene differs by eight bases from that of B.
divergens (similarity score, 99.5%). In addition, serologic
(Table 2) and morphologic (Figure 2) data support the con-
clusion that the patient was infected with a B.
divergens–like parasite. 
B. divergens infects cattle in Europe but has never been
reported to do so in the United States. The parasite that
caused the index bovine case of B. divergens infection,
which was described in 1911 (27), is unavailable for molec-
ular characterization. However, the DNA sequences of the
complete 18S rRNA gene for bovine isolates of B. diver-
gens from three European countries (6) and an isolate from
an infected Ixodes ricinus tick from another European
country (N.J. Pieniazek, unpub data) are identical; sequence
data for the complete 18S rRNA gene of B. divergens from
its tick vector have never previously been reported.
B. divergens has traditionally been considered not only
a bovine parasite but also the etiologic agent of most of the
reported zoonotic cases of babesiosis in Europe; the cases
purportedly caused by B. divergens typically have
occurred in asplenic persons, who died if not appropriately
and expeditiously treated (5). The type and quality of the
evidence used to support the conclusion that B. divergens
caused the zoonotic cases have varied markedly (5,6). To
our knowledge, sequence data for the 18S rRNAgene have
been reported for only two such cases. For one of the two
cases (28), sequence data for the complete 18S rRNAgene
were reported (EMBL data base no. AJ439713; data for
1,728 bases), which were not identical to the sequence for
bovine B. divergens (6). For the other case (29), sequence
data for a portion of the gene were reported (GenBank no.
AF435415; data for 369 bases). Some of the European
zoonotic cases attributed to B. divergens infection might
have been caused by EU1, the etiologic agent of the first
reported zoonotic cases of babesiosis in Italy and Austria,
which ocurred in 1998 and 2000, respectively (6). In
phylogenetic analysis, EU1 is most closely related to B.
odocoilei (17,19) and is secondarily related to B. divergens
(31 base differences) (6). 
Besides our case, two other U.S. zoonotic cases have
been attributed to infection with B. divergens–like
organisms, on the basis of sequence data for the 18S rRNA
gene (12,13). The first, a fatal case in Missouri in 1992,
occurred in a 73-year-old asplenic man, whose parasitemia
level was 3%–4% (12). In the original description of the
case and the etiologic agent (MO1, for “Missouri 1”) (12),
molecular data were provided for only a 128-bp fragment
(with three unresolved positions), in which MO1 and B.
divergens have identical sequences (6,12). The other U.S.
case occurred in Kentucky in 2001, in a 56-year-old
asplenic man, with a parasitemia level of 30% to 35% (13).
The sequence of the complete 18S rRNA gene of the
etiologic agent reportedly differs by three bases from that
for  B. divergens (similarity score, 99.8%). However,
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Table 2. Results of testing of serial specimens obtained from a patient in Washington State infected with a Babesia divergens–like 
parasite
a 
Date
b  Examination of smears of whole blood for Babesia parasites  IFA titers to B. divergens antigens
c  PCR 
July 31, 2002  Positive (parasitemia level, 28.2%)  1:64  Positive 
September 10  NPF  1:1,024  Positive 
October 25  NPF  1:1,024  Positive 
November 8  NPF  1:256  Negative 
December 12  NPF  1:256  Negative 
April 14, 2003  NPF  1:256  Negative 
aIFA, indirect fluorescent antibody; PCR, polymerase chain reaction; NPF, no parasites found. 
bSee Table 1 for values of other laboratory testing performed on or near dates listed here. Patient received antibabesial therapy from July 31 (before July 31 specimen 
obtained) through August 26, 2002. Hamsters injected with patient’s blood obtained July 31 and August 1 did not become demonstrably parasitemic, nor did jirds 
injected with blood from September 10.  
cAll of the serum specimens were tested at the Centers for Disease Control and Prevention on same day. 
 because no GenBank accession number was provided (13),
we do not know whether the three base differences
constitute a subset of the eight we found between our
patient’s parasite and B. divergens.  
We do not know enough about the biology of the
etiologic agents of these three U.S. cases attributed (by
molecular criteria) to infection with B. divergens–like
parasites, to conclude how closely related the parasites are
to the European bovine B. divergens. Various wild
ruminants in the United States and Europe have been
found to be infected with parasites that are considered B.
divergens–like in some respects (e.g., are in the same
phylogenetic clade, demonstrate serologic cross-reactivity
in IFA testing, have similar morphologic characteristics
[Figure 2]). Some such parasites (e.g., B. odocoilei, a
parasite of white-tailed deer [6,17,19]; 30 base differences
from B. divergens [similarity score, 98.3%]) are known to
be different species than B. divergens. However, the
classification by species of some B. divergens–like
parasites remains unresolved (6). For example, the
sequence for the complete 18S rRNA gene for a reindeer
Babesia sp. in Scotland differs by only four bases from that
of  B. divergens (similarity score, 99.8%). Although the
organism is not known to cause overt disease in local cattle
and did not infect jirds injected with several-day-old blood
from infected reindeer (30), the biologic data available to
date are not definitive. Until more parasites that are B.
divergens–like by molecular criteria, such as the parasites
that caused the three U.S. zoonotic cases, are identified
and characterized in other respects, we will not know
whether the parasites are synonymous with B. divergens or
belong to a complex of related species or strains. 
The public health importance of the B. divergens–like
organism in Washington is not yet known and may take
years to determine. Its biology, geographic distribution,
ecology, tick vector, and animal reservoir host(s), as well
as the prevalence of infection in nonhuman and human
hosts, risk factors for infection and disease in humans, and
clinical manifestations of infection must be further
investigated. We have begun our search for the tick vector;
however, no ticks were found in September 2002, after
flagging for 18 person-hours near the patient’s house.
Molecular analysis at CDC of DNA from 98 ticks of
various species, from various animals and counties in
Washington, showed that none were infected with the
patient’s parasite, but 11 were infected with B. odocoilei
(data not shown). 
The clinical aspects of our patient’s case are notable,
particularly the fact that he survived, despite critical
illness. The extent to which host (e.g., advanced age)
versus parasite factors contributed to the severity of the
case are unknown. However, even B. microti, which
traditionally has been considered less virulent than B.
divergens in humans (i.e., B. microti infection often is
asymptomatic or associated with mild, nonspecific
symptoms), has been associated with critical illness and
fatalities, particularly among elderly, asplenic, or
otherwise immunocompromised, patients (3,4,31,32). His
remarkably good physical condition for his age and the
meticulous medical care he received likely contributed to
his survival. 
We cannot generalize from his case to conclude what
constitutes optimal antimicrobial therapy for infection with
the patient’s parasite. The one clinical trial in which the
effectiveness of antimicrobial regimens for treatment of
babesiosis was evaluated included only patients who were
not severely ill and were infected with B. microti (33).
Anecdotal data and extrapolation from the literature about
treatment of malaria suggest that exchange transfusion may
be beneficial for some critically ill patients, especially for
those with signs of hemodynamic instability or high
parasitemia levels (e.g., >10%) (31,34–36). The persistence
of PCR positivity in our patient for at least 2 months after
he completed therapy (Table 2) indicates he continued to
have subpatent parasitemia, despite remaining clinically
well. Persistence of PCR positivity after treatment of
symptomatic cases of B. microti infection with clindamycin
and quinine has also been reported (37,38); PCR positivity
lasted a mean of 16 days in 22 such patients, about one third
of whom had persistent positivity for >1 month (none for
>3 months) (37).
The case we describe underscores several points for
clinicians. First, the diagnosis of babesiosis should be
considered for febrile persons with hemolytic anemia,
regardless of where they live or have traveled. Second,
babesiosis, which can be life threatening, can be caused by
novel parasites not detected by serologic or molecular
testing for B. microti or the WA1- or CA1-type parasites
(i.e., for parasites previously recognized to cause zoonotic
babesiosis in the United States). This fact underscores the
importance of manual examination of smears of blood
from patients who might have babesiosis. In most
hospitals, blood smears are examined by machines rather
than by laboratory staff, unless specific criteria are met by
the patient, certain abnormalities are “flagged” by the
machine, or manual examination is specifically requested.
Third, thorough characterization of novel Babesia spp. is
needed to advance our knowledge about zoonotic parasites
and to facilitate development of laboratory methods for
detecting such parasites in patients, participants in
epidemiologic investigations, and ultimately, perhaps,
blood donors. Characterization of novel Babesia spp.
would be facilitated if clinicians with patients likely
infected outside of the geographic areas known to be
endemic for B. microti sent fresh, pretreatment,
anticoagulated, whole blood specimens, by overnight mail,
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doing such work. 
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